| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
2015-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c52d418f6f9b1273a597a79e3a6b727d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6d60642957e1046b32dc2faa3af7082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac72ebf80161af4af3b3bc455661ed55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9d07a719693adb55ac0d9e068877242
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18d925a6ef2a98e43f7f822b30be0c5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_900fb0431f1d0f1b3ae230dafb6cef3f |
| publicationDate |
2015-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015218265-A1 |
| titleOfInvention |
Novel anti-human ngf antibody |
| abstract |
To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. An anti-human NGF antibody Fab′ fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109929035-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11260124-B2 |
| priorityDate |
2011-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |